Chronic obstructive pulmonary disease: Patho-physiology, current methods of treatment and the potential for simvastatin in disease management

Expert Opinion on Drug Delivery

Volumn 8, Issue 9, 2011, Pages 1205-1220

  Marin, Laura ^a   Colombo, Paolo ^a   Bebawy, Mary ^b   Young, Paul M ^b   Traini, Daniela ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

COPD; HMG CoA reductase inhibitors; Mechanism of action; Metabolism; Simvastatin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ATORVASTATIN; BRONCHODILATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; SIMVASTATIN; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; LUNG ALVEOLUS MACROPHAGE; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW; SIDE EFFECT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES, ALVEOLAR; MEVALONIC ACID; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIMVASTATIN;

EID: 80052079402     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.588697     Document Type: Review

References (101)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80 (Pubitemid 30490396)
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease GOLD Executive Summary. Am J Respir Crit Care Med 2007;176:532-55 (Pubitemid 47403272)
3. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005;26:142-53 (Pubitemid 40617293)
4. Szilasi M, Dolinay T, Nemes Z, Strausz J. Pathology of chronic obstructive pulmonary disease. Pathol Oncol Res 2006;12(1):52-60.
5. Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009;64:894-900
6. Barclay L. COPD disease burden heavy and increasing. Lancet 2007;370:741-50
7. Luppi F, Franco F, Beghe B, Fabbri LM. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:848-56
8. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12 (Pubitemid 46608700)
9. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83 (Pubitemid 46237383)
10. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9 (Pubitemid 34764873)
11. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-8
12. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function. Am J Respir Crit Care Med 2007;176:742-7
13. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004;1:59-70.
14. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001;18(34):50s-59s. (Pubitemid 34760609)
15. Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IKBalpha: a mechanism for NF-kB activation. Mol Cell Biol 1993;13(6):3301-10 (Pubitemid 23157268)
16. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009;30(10):475-87
17. Barnes PJ, Karin M. Nuclear factor-kappaB - A pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336:1066-71 (Pubitemid 27163860)
18. Jimi E, Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 2005;208:80-7 (Pubitemid 41746386)
19. Hippenstiel S, Schmecka B, Seybolda J, et al. Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem Pharmacol 2002;64(5-6):971-7 (Pubitemid 35232271)
20. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-9
21. Karin M, Delhase M, JNK or IKK. AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action? Proc Natl Acad Sci U S A 1998;95:9067-9 (Pubitemid 28506184)
22. Puddicombe SM, Davies DE. The role of MAP kinases in intracellular signal transduction in bronchial epithelium. Clin Exp Allergy 2000;30:7-11 (Pubitemid 30093875)
23. Shimizu S, Tahara M, Ogata S, et al. Involvement of nuclear factor-kappaB activation through RhoA/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells. Mol Hum Reprod 2007;13(3):181-7
24. Bitterman PB, Saltzman LE, Adelberg S, et al. Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung. J Clin Invest 1984;74:460-9 (Pubitemid 14053994)
25. Tomita K, Caramori G, Lim S, et al. Increased p21CIP1/WAF1 and B cell lymphoma leukemia-xL expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med 2002;166:724-31 (Pubitemid 34971857)
26. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95(3):1370-6
27. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S29-32
28. Lim S, Roche N, Oliver BG, et al. Effect of IL-10 on release of MMP-9 and TIMP-1 by AM in smokers. Am J Respir Crit Care Med 2000;162:1355-60
29. Shapiro SD, Kobayashi D, Ley TJ. Cloning and characterisation of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993;268:23824-9 (Pubitemid 23335353)
30. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008;12:361-7 (Pubitemid 351507246)
31. Ito I, Nagai S, Handa T, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005;172:1378-82 (Pubitemid 43069810)
32. Vanderslice P, Biediger RJ, Woodside DG, et al. Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm Pharmacol Ther 2004;17:1-10 (Pubitemid 37468403)
33. Springer TA. Structural basis for selectin mechanochemistry. Proc Natl Acad Sci U S A 2009;106(1):91-6
34. Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev 2003;55(7):779-91 (Pubitemid 36776793)
35. The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004;24:206-10
36. Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT-trial. Eur Respir J 2010;36:65-73
37. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89 (Pubitemid 46294610)
38. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:857-64
39. Celli BR, MacNee W; committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46 (Pubitemid 38807371)
40. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18(114):222-32.
41. Vincken W. Bronchodilator treatment of stable COPD: long-acting anticholinergics. Eur Respir Rev 2005;14(94):23-31 (Pubitemid 41277673)
42. DAgostino B, Polverino M, Cirino G, et al. Exercise capacity and cytochrome oxidase activity in muscle mitochondria of COPD patients. Respir Med 2010;104:83-90
43. Wood-Baker R, Cochrane1 B, Naughton MT. Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J 2010;40:94-101
44. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62 (Pubitemid 44570305)
45. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207-14 (Pubitemid 351860929)
46. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009;85:414-21
47. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001;17:995-1007 (Pubitemid 32600350)
48. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178(11):1139-47
49. Hunter MH, King DE. COPD: management of acute exacerbations and chronic stable disease. Am Fam Physician 2001;64(4):603-12
50. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8(30):1465-9921
51. Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 2009;6(9):897-905
52. Parlati C, Buttini F, Ammit AJ, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res 2009;26(5):1084-92
53. Adi H, Young PM, Chan HK, et al. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008;97(8):3356-66
54. Zhao M, Yao Y, Ren Y, et al. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol 2008;187(3):214-21
55. Vignola AM. PDE4 inhibitors in COPD a more selective approach to treatment. Respir Med 2004;98:495-503 (Pubitemid 38701852)
56. Barnes PJ. Theophylline. Pharmaceuticals 2010;3:725-47
57. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64
58. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21:20-7 (Pubitemid 44921816)
59. Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends Pharmacol Sci 2007;28:544-50 (Pubitemid 47488509)
60. Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60 (Pubitemid 43866389)
61. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10(45):1465-9921
62. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-34 (Pubitemid 44211783)
63. Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009;75:19-29
64. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118 (Pubitemid 40261799)
65. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93
66. Kim SE, Thuy TTTT, Lee JH, et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med 2009;41(4):277-87
67. Ou XM, Wen FQ, Uhal BD, et al. Simvastatin attenuates experimental small airway remodelling in rats. Respirology 2009;14(5):734-45
68. Kamio K, Liu XD, Sugiura H, et al. Statins inhibit matrix metalloproteinase release from human lung fibroblasts. Eur Respir J 2010;35:637-46
69. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001;5(4):378-87
70. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28
71. Mackay DJG, Hall A. Rho GTPases. J Biol Chem 1998;273:20685-8 (Pubitemid 28385341)
72. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279(5350):509-14 (Pubitemid 28067271)
73. Cammarano MS, Minden A. Dbl and the Rho GTPases Activate NFkB by IkB Kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem 2001;276(28):25876-82
74. Perona R, Montaner S, Saniger L, et al. Activation of the nuclear factor-KB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997;11:463-75 (Pubitemid 27097645)
75. Romaine SPR, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11
76. Sarr FS, Guillaume YC, Andrea C. Magnesium cation effect on passive diffusion of statin molecules: molecular chromatography approach. J Pharm Biomed Anal 2008;47:651-7
77. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity- relevance for the pharmacology and clinical effects of HMGCoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37 (Pubitemid 28094090)
78. Tubic-Grozdanis M, Hilfinger JM, Amidon GL, et al. Pharmacokinetics of the CYP3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res 2008;25:1591-600
79. Imai T. Human carboxylesterase lysoziyme-catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006;21(3):173-85
80. Bodor N, Buchwald P. Retrometabolism-based drug design and targeting. Burgers medicinal chemistry, drug discovery and development. 2010. p. 73-189
81. Guengerich FP. Cytochrome P-450 3A4 - Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17 (Pubitemid 29222549)
82. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy-acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56:120-4 (Pubitemid 36886497)
83. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191-9 (Pubitemid 27446590)
84. Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1989;18:138-45 (Pubitemid 20107705)
85. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12 (Pubitemid 34456970)
86. Igel M, Sudhop T. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42:835
87. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97(8A):6C-26C
88. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690-5 (Pubitemid 40462927)
89. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97(8A):44C-51C
90. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008;8:333-8
91. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107 (Pubitemid 32880030)
92. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105 (Pubitemid 44301483)
93. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007;82(11):1381-90 (Pubitemid 350060135)
94. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today 2006;11:458-46
95. Vestbo J, Tan L, Atkinson G, et al. A controlled trial of 6-weeks treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009;33:1039-44
96. Chapman RW, House A, Richard J, et al. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. Eur J Pharmacol 2010;643:274-81
97. Munger JS, Shi GP, Mark EA, et al. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterase. J Biol Chem 1991;266(28):18832-8 (Pubitemid 21908159)
98. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008;13:412-31
99. Hori T, Hosokawa M. DNA methylation and its involvement in Carboxylesterase 1A1 (CES1A1) gene expression. Xenobiotica 2010;40(2):119-28
100. Anttila S, Hukkanen J, Hakkola J, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 1997;16(3):242-9 (Pubitemid 127497446)
101. Piipari R, Savela K, Nurminen T, et al. Expression of CYP1A1, CYP1B1 and CYP3A and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer 2000;86:610-16 (Pubitemid 30249869)